{"id":254347,"date":"2012-09-04T15:15:39","date_gmt":"2012-09-04T15:15:39","guid":{"rendered":"http:\/\/www.eugenesis.com\/jonathan-divincenzo-joins-enzymatics-as-president-and-chief-executive-officer\/"},"modified":"2012-09-04T15:15:39","modified_gmt":"2012-09-04T15:15:39","slug":"jonathan-divincenzo-joins-enzymatics-as-president-and-chief-executive-officer","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/biology\/jonathan-divincenzo-joins-enzymatics-as-president-and-chief-executive-officer.php","title":{"rendered":"Jonathan DiVincenzo Joins Enzymatics as President and Chief Executive Officer"},"content":{"rendered":"<p><p>    BEVERLY, Mass.--(BUSINESS WIRE)--  <\/p>\n<p>    Enzymatics, Inc., a rapidly growing provider of molecular    biology reagents, today announced the appointment of Jonathan    DiVincenzo as President and Chief Executive Officer. Mr.    DiVincenzo brings more than 20 years of industry experience to    the role having previously served as Corporate Officer of    Millipore Corporation andPresident of its Bioscience    Division. Mr. DiVincenzo joins Enzymatics to continue the    growth fueled by the immense scientific skill set, drive and    ambition of the Companys workforce.  <\/p>\n<p>    Jon is a visionary leader with a strong track record of    building global businesses serving the life science industry,\"    said Ian Ratcliffe, Chairman of Enzymatics Board of Directors.    \"His experience and capabilities in bringing new technologies    to global markets make him uniquely qualified to lead    Enzymatics through its next wave of growth.\"  <\/p>\n<p>    Enzymatics co-founders Stephen Picone and Christopher Benoit    commented, Enzymatics has evolved into a thriving business    from a startup in 2007, growing to approximately 100 employees    in just five years. We welcome Jon to the Enzymatics family,    and with his extensive commercial and strategic experience, we    will continue to build Enzymatics as the leading global    supplier of high quality reagents and services to the rapidly    expanding molecular genetics industry. Stephen Picone and    Chris Benoit are remaining at the Company in active roles under    the new titles, Chief Strategy Officer and Chief Commercial    Officer, respectively.  <\/p>\n<p>    Mr. DiVincenzo has held several key leadership positions during    his 18-year tenure at Millipore Corporation (now Merck    Millipore).As the President of the Companys Bioscience    Division, Jon led 1200 employees and grew the division to over    $600 million of revenues. Prior to that he served as Vice    President of Global Sales and Service and as Vice President of    Marketing and R&D. For several years, he also held senior    marketing and product management positions within Millipores    Lab Water business (which later became part of the Bioscience    Division) in Paris. Before Millipore, Jon worked for Orion    Research (now part of ThermoFisher Scientific) as Product    Manager and Technical Support Engineer and for General Electric    Corporation in thermodynamics engineering. Jon holds a Bachelor    of Science degree in Mechanical Engineering from Northeastern    University in Boston. He is a member of the Northeasterns    College of Engineering Advisory Board and Board of Directors of    the Analytical and Life Science Systems Association (ALSSA).  <\/p>\n<p>    About Enzymatics  <\/p>\n<p>    Enzymatics is a leading provider of molecular biology reagents    and manufacturing services that delivers unrivaled quality,    consistency, and value to the commercial genomic sciences    community. The company manufactures in the USA under ISO 13485    certification, is focused on building long-term partnerships,    and leverages internal and external innovation to commercialize    breakthrough technologies.     <a href=\"http:\/\/www.enzymatics.com\" rel=\"nofollow\">http:\/\/www.enzymatics.com<\/a>  <\/p>\n<p>    Photos\/MultimediaGallery Available:     <a href=\"http:\/\/www.businesswire.com\/cgi-bin\/mmg.cgi?eid=50394385&#038;lang=en\" rel=\"nofollow\">http:\/\/www.businesswire.com\/cgi-bin\/mmg.cgi?eid=50394385&#038;lang=en<\/a>  <\/p>\n<p>    MULTIMEDIA AVAILABLE:<a href=\"http:\/\/www.businesswire.com\/cgi-bin\/mmg.cgi?eid=50394385&#038;lang=en\" rel=\"nofollow\">http:\/\/www.businesswire.com\/cgi-bin\/mmg.cgi?eid=50394385&#038;lang=en<\/a>  <\/p>\n<\/p>\n<p>See the article here:<br \/>\n<a target=\"_blank\" href=\"http:\/\/finance.yahoo.com\/news\/jonathan-divincenzo-joins-enzymatics-president-140000946.html;_ylt=A2KJNF8VG0ZQlWcAIUL_wgt.\" title=\"Jonathan DiVincenzo Joins Enzymatics as President and Chief Executive Officer\">Jonathan DiVincenzo Joins Enzymatics as President and Chief Executive Officer<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> BEVERLY, Mass.--(BUSINESS WIRE)-- Enzymatics, Inc., a rapidly growing provider of molecular biology reagents, today announced the appointment of Jonathan DiVincenzo as President and Chief Executive Officer. Mr.  <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/biology\/jonathan-divincenzo-joins-enzymatics-as-president-and-chief-executive-officer.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":57,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[577690],"tags":[],"class_list":["post-254347","post","type-post","status-publish","format-standard","hentry","category-biology"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/254347"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/57"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=254347"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/254347\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=254347"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=254347"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=254347"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}